TOLTERODINE NEO CINFA 4 mg PROLONGED-RELEASE HARD CAPSULES

2. What you need to know before taking tolterodine neo cinfa

Do not take tolterodine neo cinfa

• If you are allergic to tolterodine tartrate or any of the other components of this medication (listed in section 6).
• If you are unable to empty your bladder (urinary retention).
• If you have uncontrolled narrow-angle glaucoma (high intraocular pressure with loss of vision, which is not being treated properly).
• If you have myasthenia gravis (excessive muscle weakness).
• If you have severe ulcerative colitis (ulceration and inflammation in the colon).
• If you have toxic megacolon (acute dilation of the colon).

Warnings and precautions

• If you have difficulty urinating and/or urinate with a weak or slow stream.
• If you have a gastrointestinal disorder that affects the passage and/or digestion of food.
• If you have kidney problems (renal insufficiency).
• If you have liver disease.
• If you have neuronal disorders that affect your blood pressure, intestinal function, or sexual function (any autonomic nervous system neuropathy).
• If you have a hiatal hernia (hernia in an abdominal organ).
• If you ever notice a decrease in bowel movements or have severe constipation (decreased gastrointestinal motility).
• If you have any relevant heart conditions, such as:
• abnormal heart rhythm (ECG)
• slow heart rate (bradycardia)
• pre-existing heart conditions, such as:
• cardiomyopathy (weakness in the heart muscle)
• myocardial ischemia (decreased blood flow to the heart)
• arrhythmia (irregular heart rhythm)
• heart failure
• If you have abnormally low blood levels of potassium (hypokalemia), calcium (hypocalcemia), or magnesium (hypomagnesemia).

Consult your doctor or pharmacist before starting to take tolterodine neo cinfa.

Taking tolterodine neo cinfa with other medications

Tolterodine tartrate, the active substance of tolterodine neo, may interact with other medications. It is not recommended to use tolterodine in combination with:

• Certain antibiotics (e.g., erythromycin and clarithromycin).
• Medications used to treat fungal infections (e.g., ketoconazole and itraconazole).
• Medications for the treatment of HIV.

Tolterodine neo should be used with caution when administered in combination with:

• Certain medications that affect food transit (e.g., metoclopramide and cisapride).
• Medications for the treatment of irregular heart rhythm (e.g., amiodarone, sotalol, quinidine, and procainamide)
• Other medications that have a similar mechanism of action to tolterodine (antimuscarinic properties) or medications that have an opposite mechanism of action to tolterodine neo (cholinergic properties). Consult your doctor if you are unsure.

Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take other medications, including those obtained without a prescription.

Taking tolterodine neo cinfa with food and drinks

Tolterodine neo can be taken before, during, or after a meal.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medication.

Pregnancy

You should not use tolterodine neo if you are pregnant.

Breastfeeding

It is unknown whether tolterodine is excreted in breast milk. The use of tolterodine neo is not recommended during breastfeeding.

Consult your doctor or pharmacist before using any medication.

Driving and using machines

Tolterodine neo may make you feel dizzy, tired, or affect your vision; your ability to drive or operate machinery may be impaired.

tolterodine neo cinfa contains lactose

This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.

tolterodine neo cinfa contains sodium

This medication contains less than 23 mg of sodium (1 mmol) per capsule; it is essentially "sodium-free".

3. How to take tolterodine neo cinfa

Dose:

Follow the administration instructions for this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.

The recommended dose is one 4 mg capsule per day, except in patients with liver or kidney disease, or bothersome side effects, in which case your doctor may reduce your dose to 2 mg per day.

The use of tolterodine neo is not recommended in children.

Tolterodine neo is taken orally. The capsules should be swallowed whole. Do not chew the capsules.

If you take more tolterodine neo cinfa than you should

If you or anyone else takes too many prolonged-release capsules, consult your doctor or pharmacist immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take tolterodine neo cinfa

If you forget to take a dose, take it as soon as you can. However, if it is almost time for your next dose, wait for the next dose and take it at the usual time. In this case, continue taking the capsules as directed by your doctor.

Do not take a double dose to make up for forgotten doses.

If you stop taking tolterodine neo cinfa

Your doctor will indicate the duration of your treatment with tolterodine neo. Do not stop treatment before if you do not see an immediate effect, as your bladder needs time to adapt to it. Complete the treatment with the prolonged-release capsules prescribed by your doctor. If you do not notice any effect, consult your doctor.

The benefit of treatment should be reevaluated after 2-3 months of use. Always consult your doctor if you are thinking of stopping treatment.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone will experience them.

You should consult your doctor immediately if you notice symptoms of angioedema, such as:

• Swelling of the face, tongue, or pharynx.
• Difficulty swallowing.
• Hives and difficulty breathing.

In addition, you should seek medical attention if you experience a hypersensitivity reaction (e.g., itching, rash, hives, and difficulty breathing). This occurs rarely (may affect up to 1 in 100 patients).

Inform your doctor or pharmacist if you experience:

• Chest pain, difficulty breathing or tiredness (even at rest), difficulty breathing at night, swelling of the legs.
• These may be symptoms of heart failure. This occurs rarely (may affect up to 1 in 100 patients).

The following side effects have been observed during treatment with tolterodine, with the following frequencies:

Very common side effects(may affect more than 1 in 10 patients):

• Dry mouth
• Headache

Common side effects(may affect up to 1 in 10 patients):

• Bronchitis
• Dizziness, drowsiness, finger cramps
• Dry eyes, blurred vision
• Vertigo
• Palpitations
• Difficulty digesting (dyspepsia), constipation, abdominal pain, excessive gas in the stomach or intestines, vomiting.
• Dry skin
• Difficulty urinating, inability to empty the bladder
• Tiredness, chest pain, swelling due to fluid accumulation (e.g., in the ankles)
• Weight gain

Uncommon side effects(may affect up to 1 in 100 patients):

• Allergic reactions
• Nervousness
• Finger cramps
• Increased heart rate, heart failure, irregular heartbeat
• Heartburn
• Memory impairment

Additional reactions reported include severe allergic reactions, confusion, hallucinations, increased heart rate, red skin, and angioedema, and disorientation. Cases of worsening dementia symptoms have been reported in patients being treated for dementia.

If you consider any of the side effects you are experiencing to be serious or if you notice any side effect not mentioned in this package leaflet, inform your doctor or pharmacist.

Reporting side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.

5. Storage of tolterodine neo cinfa

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated.

Do not store above 25°C.

Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the pharmacy's SIGRE collection point. If you are unsure, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.

6. Package contents and additional information

Composition of tolterodine neo cinfa

• The active substance of tolterodine neo cinfa is tolterodine tartrate. Each prolonged-release hard capsule contains 4 mg of tolterodine tartrate, equivalent to 2.74 mg of tolterodine.
• The other components are: lactose monohydrate, microcrystalline cellulose, polyvinyl acetate, povidone, anhydrous colloidal silica, sodium lauryl sulfate, sodium docusate, magnesium stearate (E-470b), and hypromellose.

Coating: Ethylcellulose, triethyl citrate, ethyl acrylate-methyl methacrylate copolymer (30% dispersion), and 1,2-propylene glycol.

Capsule composition: Indigo carmine (E-132), titanium dioxide (E-171), and gelatin.

Appearance of the product and package contents

The 4 mg prolonged-release hard capsules of tolterodine neo cinfa are light blue opaque-hard gelatin capsules that contain four white, round, and biconvex coated tablets.

Tolterodine neo cinfa 4 mg prolonged-release hard capsules are available in the following package sizes:

Blisters of 7, 14, 28, 49, 84, and 98 prolonged-release hard capsules.

Not all package sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Poligono Industrial Areta

31620 Huarte (Navarra) - Spain

Manufacturer

Pharmathen, S.A.

6, Dervenakion Str.

Pallini Attiki

15351 Greece

or

Pharmathen International, S.A.

Industrial Park Sapes,

Rodopi Prefecture, Block no. 5

Rodopi 69300

Greece

Date of the last revision of this package leaflet:August 2020

Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

You can access detailed and updated information about this medication by scanning the QR code included in the package leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/77250/P_77250.html

QR code to: https://cima.aemps.es/cima/dochtml/p/77250/P_77250.html